Synlogic dropped $1.34 (28%) to $3.49 after announcing the discontinuation of its lead program, SYNB1020 for hyperammonemia, based on interim Phase Ib/IIa data showing futility.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,